Bictegravir/emtricitabine/tenofovir alafenamide

Drug Profile

Bictegravir/emtricitabine/tenofovir alafenamide

Alternative Names: Bictegravir/F/TAF; Emtricitabine/GS 9883/tenofovir alafenamide; F/GS 9883/TAF; GS 9883/F/TAF; GS 9883/tenofovir alafenamide/emtricitabine; GS-9883/emtricitabine/tenofovir alafenamide

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Antivirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections

Most Recent Events

  • 18 Apr 2017 Gilead Sciences plans a phase III trial for HIV-1 infections (NCT03110380)
  • 01 Sep 2016 Phase-II/III clinical trials in HIV-1 infections (In adolescents, In children) in USA (PO) (NCT02881320)
  • 01 Feb 2016 Gilead Sciences initiates enrollment in a phase III trial for HIV-1 infection (Treatment-experienced) in USA (PO) (NCT02652624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top